OTCMKTS:SBMFF

Sino Biopharmaceutical Competitors

$1.06

0.00 (0.00 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.06

Now: $1.06▼

$1.06

50-Day Range

$0.94

MA: $1.05▼

$1.20

52-Week Range

$0.84

Now: $1.06▼

$1.92

VolumeN/A

Average Volume5,315 shs

Market Capitalization$19.92 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.57

Sino Biopharmaceutical (OTCMKTS:SBMFF) Vs. ATLKY, AIQUY, SHECY, KDDIY, ESLOY, and DPSGY

Should you be buying SBMFF stock or one of its competitors? Companies in the industry of "private households" are considered alternatives and competitors to Sino Biopharmaceutical, including Atlas Copco (ATLKY), L'Air Liquide (AIQUY), Shin-Etsu Chemical (SHECY), KDDI (KDDIY), EssilorLuxottica Société anonyme (ESLOY), and Deutsche Post (DPSGY).

Sino Biopharmaceutical vs. Atlas Copco Stock

Atlas Copco (OTCMKTS:ATLKY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap industrial products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Institutional & Insider Ownership

0.6% of Atlas Copco shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Atlas Copco has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Atlas Copco and Sino Biopharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atlas Copco	2	6	2	1	2.18
Sino Biopharmaceutical	0	2	1	0	2.33

Profitability

This table compares Atlas Copco and Sino Biopharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atlas Copco	14.71%	26.53%	12.69%
Sino Biopharmaceutical	N/A	N/A	N/A

Earnings & Valuation

This table compares Atlas Copco and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atlas Copco	$10.98 billion	7.23	$1.75 billion	$1.44	45.38
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A

Atlas Copco has higher revenue and earnings than Sino Biopharmaceutical.

Summary

Atlas Copco beats Sino Biopharmaceutical on 10 of the 11 factors compared between the two stocks.

Sino Biopharmaceutical vs. L'Air Liquide Stock

L'Air Liquide (OTCMKTS:AIQUY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.2% of L'Air Liquide shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

L'Air Liquide has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for L'Air Liquide and Sino Biopharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
L'Air Liquide	0	4	5	0	2.56
Sino Biopharmaceutical	0	2	1	0	2.33

Profitability

This table compares L'Air Liquide and Sino Biopharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
L'Air Liquide	N/A	N/A	N/A
Sino Biopharmaceutical	N/A	N/A	N/A

Earnings and Valuation

This table compares L'Air Liquide and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
L'Air Liquide	$24.55 billion	3.23	$2.51 billion	$1.07	31.35
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A

L'Air Liquide has higher revenue and earnings than Sino Biopharmaceutical.

Summary

L'Air Liquide beats Sino Biopharmaceutical on 6 of the 7 factors compared between the two stocks.

Sino Biopharmaceutical vs. Shin-Etsu Chemical Stock

Shin-Etsu Chemical (OTCMKTS:SHECY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.1% of Shin-Etsu Chemical shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Shin-Etsu Chemical has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Shin-Etsu Chemical and Sino Biopharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shin-Etsu Chemical	0	0	2	0	3.00
Sino Biopharmaceutical	0	2	1	0	2.33

Profitability

This table compares Shin-Etsu Chemical and Sino Biopharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shin-Etsu Chemical	19.72%	10.75%	9.14%
Sino Biopharmaceutical	N/A	N/A	N/A

Earnings and Valuation

This table compares Shin-Etsu Chemical and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shin-Etsu Chemical	$14.20 billion	5.27	$2.89 billion	$1.70	26.41
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A

Shin-Etsu Chemical has higher revenue and earnings than Sino Biopharmaceutical.

Summary

Shin-Etsu Chemical beats Sino Biopharmaceutical on 9 of the 10 factors compared between the two stocks.

Sino Biopharmaceutical vs. KDDI Stock

KDDI (OTCMKTS:KDDIY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.1% of KDDI shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

KDDI has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for KDDI and Sino Biopharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KDDI	0	2	1	0	2.33
Sino Biopharmaceutical	0	2	1	0	2.33

Profitability

This table compares KDDI and Sino Biopharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KDDI	12.78%	13.56%	6.91%
Sino Biopharmaceutical	N/A	N/A	N/A

Earnings and Valuation

This table compares KDDI and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KDDI	$48.18 billion	1.52	$5.89 billion	$1.27	12.54
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A

KDDI has higher revenue and earnings than Sino Biopharmaceutical.

Summary

KDDI beats Sino Biopharmaceutical on 6 of the 8 factors compared between the two stocks.

Sino Biopharmaceutical vs. EssilorLuxottica Société anonyme Stock

EssilorLuxottica Société anonyme (OTCMKTS:ESLOY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.3% of EssilorLuxottica Société anonyme shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares EssilorLuxottica Société anonyme and Sino Biopharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EssilorLuxottica Société anonyme	N/A	N/A	N/A
Sino Biopharmaceutical	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for EssilorLuxottica Société anonyme and Sino Biopharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EssilorLuxottica Société anonyme	1	4	5	0	2.40
Sino Biopharmaceutical	0	2	1	0	2.33

Earnings and Valuation

This table compares EssilorLuxottica Société anonyme and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EssilorLuxottica Société anonyme	$19.48 billion	3.67	$1.21 billion	$2.46	33.09
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A

EssilorLuxottica Société anonyme has higher revenue and earnings than Sino Biopharmaceutical.

Risk & Volatility

EssilorLuxottica Société anonyme has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Summary

EssilorLuxottica Société anonyme beats Sino Biopharmaceutical on 6 of the 7 factors compared between the two stocks.

Sino Biopharmaceutical vs. Deutsche Post Stock

Sino Biopharmaceutical (OTCMKTS:SBMFF) and Deutsche Post (OTCMKTS:DPSGY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

0.1% of Deutsche Post shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Sino Biopharmaceutical and Deutsche Post's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sino Biopharmaceutical	N/A	N/A	N/A
Deutsche Post	3.94%	17.69%	4.87%

Analyst Ratings

This is a summary of current ratings and target prices for Sino Biopharmaceutical and Deutsche Post, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sino Biopharmaceutical	0	2	1	0	2.33
Deutsche Post	0	4	10	0	2.71

Earnings & Valuation

This table compares Sino Biopharmaceutical and Deutsche Post's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sino Biopharmaceutical	$3.51 billion	5.68	$391.67 million	N/A	N/A
Deutsche Post	$70.95 billion	1.00	$2.94 billion	$2.34	24.50

Deutsche Post has higher revenue and earnings than Sino Biopharmaceutical.

Volatility and Risk

Sino Biopharmaceutical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Deutsche Post has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Summary

Deutsche Post beats Sino Biopharmaceutical on 9 of the 10 factors compared between the two stocks.